- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | Enzolytics, Inc.: Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator | 257 | ACCESSWIRE | FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT ALLEN, TX / ACCESSWIRE / September 18, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Department of... ► Artikel lesen | |
| 09.09. | Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement | 385 | ACCESSWIRE | ALLEN, TX / ACCESSWIRE / September 9, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company and the Stephan Angeloff Institute of Microbiology,... ► Artikel lesen | |
| 20.08. | Enzolytics, Inc.: Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells | 302 | ACCESSWIRE | ALLEN, TX / ACCESSWIRE / August 20, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that a study conducted at the Ministry of Health National Centre of Infectious... ► Artikel lesen | |
| 31.07. | Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications | 431 | ACCESSWIRE | As well as Diabetes, Multiple Sclerosis and Other Diseases ALLEN, TX / ACCESSWIRE / July 31, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company... ► Artikel lesen | |
| 29.07. | Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd. | 217 | ACCESSWIRE | Updates on Results of Litigation ALLEN, TX / ACCESSWIRE / July 29, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered into a 4 year Collaboration... ► Artikel lesen | |
| 26.07. | Enzolytics, Inc.: Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release | 467 | ACCESSWIRE | ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam... ► Artikel lesen | |
| 01.07. | Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment | 288 | ACCESSWIRE | Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company is entering into a worldwide... ► Artikel lesen | |
| ENZOLYTICS Aktie jetzt für 0€ handeln | |||||
| 03.06. | Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology | 374 | ACCESSWIRE | ALLEN, TX / ACCESSWIRE / June 3, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") is thrilled to announce that the Company and Sagaliam Acquisition Corp ("SAGA") are negotiating... ► Artikel lesen | |
| 22.05. | Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation | 348 | ACCESSWIRE | Updates on ETC Marketing, Inc and Ownership of ITV-1 and IPFALLEN, TX / ACCESSWIRE / May 22, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered... ► Artikel lesen | |
| 02.05. | Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment | 308 | ACCESSWIRE | ALLEN, TX / ACCESSWIRE / May 2, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the plan to form ETC Marketing Inc. ("ETC Marketing") in partnership with Third Coast Fulfillment... ► Artikel lesen | |
| 26.04. | Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc. | 553 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC... ► Artikel lesen | |
| 23.04. | Enzolytics, Inc.: Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada | 316 | ACCESSWIRE | Offers Update on OTC Annual Report and Business Model ALLEN, TX / ACCESSWIRE / April 23, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com)(the "Company") today disclosed that on April 9, 2024... ► Artikel lesen | |
| 12.04. | Enzolytics, Inc.: Update on Formulation of New Business Strategy | 414 | ACCESSWIRE | INFORMATION ON ENZOLYTICS, INC.BOARD OF DIRECTORS AND CHIEF EXECUTIVE OFFICERUPDATE ON FORMULATION OF NEW BUSINESS STRATEGYALLEN, TX / ACCESSWIRE / April 12, 2024 / Enzolytics, Inc. (OTC PINK:ENZC)... ► Artikel lesen | |
| 20.11.23 | Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure | 361 | ACCESSWIRE | Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. ProgressALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/"https://enzolytics.com/).... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 52,55 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
| QIAGEN | 40,415 | +0,52 % | ANALYSE-FLASH: UBS belässt Qiagen auf 'Neutral' - Ziel 50 Euro | ZÜRICH (dpa-AFX) - Die Schweizer Großbank UBS hat Qiagen nach Quartalszahlen auf "Neutral" mit einem Kursziel von 50 Euro belassen. Der Labordienstleister habe dank des starken organischen Umsatzwachstums... ► Artikel lesen | |
| DYNE THERAPEUTICS | 34,150 | 0,00 % | Dyne Therapeutics GAAP EPS of -$0.96 misses by $0.25 | ||
| EVOTEC | 8,550 | -0,18 % | BASF, Evotec, HelloFresh, Sartorius, TeamViewer, Washtec - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| NUVALENT | 90,27 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results | Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 14,060 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 34,590 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,310 | 0,00 % | Recursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed Combination | Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated closeSalt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq:... ► Artikel lesen | |
| BIONTECH | 106,30 | +0,66 % | Biontech sitzt auf riesigem Finanzpolster | Im abgelaufenen Quartal wartet Biontech mit einem Umsatzsprung auf und schreibt schwarze Zahlen. Für das Gesamtjahr sieht es dagegen nicht ganz so gut aus. Die finanzielle Ausstattung stimmt wiederum.... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,470 | 0,00 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,77 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 7,750 | 0,00 % | Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results | Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,470 | 0,00 % | ADMA Biologics-Aktie erreicht Allzeithoch von 21,25 US-Dollar | ||
| 89BIO | 8,920 | 0,00 % | 89bio slips after $125 million stock deal | ||
| PHATHOM PHARMACEUTICALS | 9,740 | 0,00 % | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report |
Das Unternehmen ENZOLYTICS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENZOLYTICS INC finden Sie auf Wallstreet Online.
